CTI BioPharma Corp.
Index- P/E- EPS (ttm)-1.07 Insider Own0.10% Shs Outstand97.75M Perf Week24.79%
Market Cap389.93M Forward P/E- EPS next Y-0.02 Insider Trans4.14% Shs Float72.44M Perf Month-6.34%
Income-97.90M PEG- EPS next Q-0.42 Inst Own54.00% Short Float12.97% Perf Quarter91.77%
Sales- P/S- EPS this Y-47.40% Inst Trans10.38% Short Ratio1.47 Perf Half Y63.47%
Book/sh0.04 P/B110.75 EPS next Y27.00% ROA-103.60% Target Price9.53 Perf Year95.15%
Cash/sh0.74 P/C5.96 EPS next 5Y- ROE-232.40% 52W Range1.43 - 5.76 Perf YTD78.63%
Dividend- P/FCF- EPS past 5Y10.20% ROI- 52W High-23.09% Beta1.10
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low209.79% ATR0.47
Employees121 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)48.28 Volatility10.05% 10.15%
OptionableYes Debt/Eq12.47 EPS Q/Q-87.30% Profit Margin- Rel Volume0.43 Prev Close4.40
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume6.38M Price4.43
Recom1.70 SMA20-6.86% SMA50-4.53% SMA20044.43% Volume2,726,550 Change0.68%
Aug-09-21Initiated BTIG Research Buy $7
May-06-21Initiated Stifel Buy $5.50
Jun-24-20Resumed JMP Securities Mkt Outperform $3
Mar-05-19Initiated Lake Street Buy $4
Mar-26-18Initiated Needham Buy $10
Mar-07-18Initiated JMP Securities Mkt Outperform $8
Sep-12-17Initiated Jefferies Buy $7.50
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
May-13-22 12:19PM  
May-12-22 05:45PM  
May-10-22 07:00AM  
May-05-22 04:05PM  
Apr-28-22 04:05PM  
Apr-14-22 07:00AM  
Apr-06-22 04:05PM  
Mar-31-22 05:15PM  
Mar-16-22 10:00AM  
Mar-02-22 04:05PM  
Feb-28-22 08:02PM  
Feb-18-22 04:05PM  
Jan-06-22 04:30PM  
Dec-13-21 09:00AM  
Dec-11-21 11:59AM  
Dec-03-21 07:24AM  
Dec-02-21 04:30PM  
Dec-01-21 01:41PM  
Nov-30-21 05:30PM  
Nov-29-21 07:00AM  
Nov-26-21 08:53AM  
Nov-09-21 04:05PM  
Nov-04-21 09:01AM  
Oct-14-21 04:05PM  
Oct-05-21 10:05AM  
Oct-04-21 12:22PM  
Oct-01-21 04:05PM  
Sep-28-21 04:05PM  
Sep-17-21 04:05PM  
Sep-08-21 09:10PM  
Aug-26-21 04:52PM  
Aug-25-21 07:30AM  
Aug-24-21 07:00AM  
Aug-07-21 10:30PM  
Aug-05-21 04:05PM  
Jul-29-21 07:00AM  
Jul-26-21 04:30PM  
Jul-09-21 12:48AM  
Jun-23-21 04:30PM  
Jun-09-21 06:45PM  
Jun-02-21 12:00AM  
Jun-01-21 04:05PM  
May-26-21 04:30PM  
May-14-21 10:25AM  
May-12-21 08:34PM  
May-05-21 07:00AM  
Apr-21-21 11:28PM  
Apr-07-21 07:00AM  
Apr-02-21 03:54PM  
Mar-31-21 11:50PM  
Mar-22-21 01:00PM  
Mar-17-21 04:05PM  
Mar-12-21 07:00AM  
Mar-08-21 11:18PM  
Feb-24-21 06:30PM  
Feb-10-21 11:55PM  
Jan-28-21 10:58PM  
Jan-01-21 07:04AM  
Dec-08-20 07:00AM  
Dec-06-20 12:30PM  
Dec-02-20 10:24PM  
Nov-30-20 07:00AM  
Nov-10-20 04:05PM  
Nov-04-20 11:41AM  
Nov-02-20 04:05PM  
Oct-26-20 11:55PM  
Oct-13-20 07:00AM  
Oct-01-20 06:52PM  
Sep-30-20 07:45AM  
Sep-29-20 04:05PM  
Aug-06-20 04:05PM  
Jul-17-20 09:54AM  
Jul-06-20 07:47PM  
Jun-22-20 03:27PM  
Jun-01-20 04:22PM  
May-28-20 07:00AM  
May-18-20 06:25AM  
Apr-27-20 07:00AM  
Apr-08-20 07:00AM  
Mar-27-20 07:00AM  
Mar-12-20 04:05PM  
Mar-06-20 06:48PM  
Feb-21-20 04:22PM  
Feb-14-20 07:00AM  
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Craig Adam RPresident and CEODec 02Buy1.523,5005,33713,500Dec 02 05:16 PM